Mark Erlander, Cardiff Oncology CEO

Cardiff drops its prostate can­cer pro­gram, send­ing shares in­to a tail­spin

Cardiff On­col­o­gy is join­ing the league of com­pa­nies that have de­cid­ed to scrap one of its pro­gram, lead­ing the com­pa­ny’s stock to take a nose dive on Tues­day.

The com­pa­ny an­nounced that it will no longer fund its clin­i­cal tri­als for prostate can­cer and in­stead will fo­cus its ef­forts on pan­cre­at­ic and metasta­t­ic col­orec­tal can­cer.

The com­pa­ny is test­ing its lead can­di­date, on­va­nsert­ib, a PLK1 in­hibitor, along with the stan­dard of care in a va­ri­ety of in­di­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.